A carregar...
Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
Epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer (NSCLC) patients benefit from EGFR tyrosine kinase inhibitors (TKIs), while some patients demonstrate a resistance to EGFR‐TKIs. In the case reported here, the NSCLC patient harboring an EGFR‐sensitive mutation and...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7471017/ https://ncbi.nlm.nih.gov/pubmed/32744377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13583 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|